-
England 'flat' as Crawley admits Australia a better side
-
Australia four wickets from Ashes glory as England cling on
-
Beetles block mining of Europe's biggest rare earths deposit
-
French culture boss accused of mass drinks spiking to humiliate women
-
NBA champions Thunder suffer rare loss to Timberwolves
-
Burning effigy, bamboo crafts at once-a-decade Hong Kong festival
-
Joshua knocks out Paul to win Netflix boxing bout
-
Dogged Hodge ton sees West Indies save follow-on against New Zealand
-
England dig in as they chase a record 435 to keep Ashes alive
-
Wembanyama 26-point bench cameo takes Spurs to Hawks win
-
Hodge edges towards century as West Indies 310-4, trail by 265
-
US Afghans in limbo after Washington soldier attack
-
England lose Duckett in chase of record 435 to keep Ashes alive
-
Australia all out for 349, set England 435 to win 3rd Ashes Test
-
US strikes over 70 IS targets in Syria after attack on troops
-
Australian lifeguards fall silent for Bondi Beach victims
-
Trump's name added to Kennedy Center facade, a day after change
-
West Indies 206-2, trail by 369, after Duffy's double strike
-
US strikes Islamic State group in Syria after deadly attack on troops
-
Epstein files opened: famous faces, many blacked-out pages
-
Ravens face 'special' Patriots clash as playoffs come into focus
-
Newly released Epstein files: what we know
-
Musk wins US court appeal of $56 bn Tesla pay package
-
US judge voids murder conviction in Jam Master Jay killing
-
Trump doesn't rule out war with Venezuela
-
Haller, Aouar out of AFCON, Zambia coach drama
-
Nasdaq rallies again while yen falls despite BOJ rate hike
-
Bologna win shoot-out with Inter to reach Italian Super Cup final
-
Brandt and Beier send Dortmund second in Bundesliga
-
Trump administration begins release of Epstein files
-
UN Security Council votes to extend DR Congo mission by one year
-
Family of Angels pitcher, club settle case over 2019 death
-
US university killer's mystery motive sought after suicide
-
Rubio says won't force deal on Ukraine as Europeans join Miami talks
-
Burkinabe teen behind viral French 'coup' video has no regrets
-
Brazil court rejects new Bolsonaro appeal against coup conviction
-
Three-time Grand Slam winner Wawrinka to retire in 2026
-
Man Utd can fight for Premier League title in next few years: Amorim
-
Pandya blitz powers India to T20 series win over South Africa
-
Misinformation complicated Brown University shooting probe: police
-
IMF approves $206 mn aid to Sri Lanka after Cyclone Ditwah
-
US halts green card lottery after MIT professor, Brown University killings
-
Stocks advance as markets cheer weak inflation
-
Emery says rising expectations driving red-hot Villa
-
Three killed in Taipei metro attacks, suspect dead
-
Seven Colombian soldiers killed in guerrilla attack: army
-
Amorim takes aim at Man Utd youth stars over 'entitlement'
-
Mercosur meets in Brazil, EU eyes January 12 trade deal
-
US Fed official says no urgency to cut rates, flags distorted data
-
Rome to charge visitors for access to Trevi Fountain
Brazilian ritual root gets second life as potential anti-depressant
Long used in Indigenous Brazilian rituals, the jurema preta plant, which contains a potent psychedelic, is gaining ground as a potential treatment for depression.
At street stalls where medicinal herbs are sold, customers can buy the plant's root which contains dimethyltryptamine (DMT), a hallucinogenic substance that researchers say could be used to alleviate symptoms.
Following instructions he found on the internet, Guaracy Carvajal extracted DMT at home in 2016 from roots he bought on the street.
The 31-year-old software programmer, who had tried various treatment for chronic depression he has suffered since adolescence, said the drug makes it "feel like you've solved something in your life."
Physicist Draulio Araujo, who has conducted extensive research on the drug, said "the response is rapid. One day after treatment, (patients) already showed a significant improvement in their depression symptoms."
Yet he also warned that it "is not a magic cure" and that psychedelics "are not for everyone."
As a researcher at the Brain Institute of the Federal University of Rio Grande do Norte, Araujo and his team treated 14 people with the drug for six months.
The patients inhaled vaporized DMT, under medical supervision.
"It's common for our patients to say that something changed, that a key opened something," he said.
His patients also received psychological therapy, and some continued with conventional pharmaceutical drugs.
Neuroscientist Fernanda Palhano-Fontes, also of the Brain Institute, said "we have patients who improve significantly, others who don't improve at all."
Araujo's findings were published in the scientific journal Nature in April. In 2024, he published another study with promising results in the journal Psychedelic Medicine.
As for Carvajal, who stopped using jurema preta some time ago, he said the drug really allows a person to "start to have a lighter life."
It helped him get through a time when he was in "a state of questioning myself" about "work, day-to-day life," he said.
- Spiritual channels -
Brazil occupies a fairly prominent place in DMT research due to the substance's prominence in society, Araujo said.
While there is no ban on the cultivation or possession of jurema, which is also known as Mimosa tenuiflora, consumption of DMT is prohibited, except for religious and scientific use.
Jurema's roots are combined with other plants in a wine-like beverage that is consumed at rituals that include dancing and drums, part of Indigenous tradition in northeast Brazil where the plant grows.
"It's not hallucination," said Joyce Souza, a young woman attending a jurema ceremony in Planaltina, on the outskirts of Brasília.
"My spiritual channels become more accessible, I can communicate better with myself," Souza said.
Gathered in a house courtyard and dressed in white, the group of mostly novices waited for more seasoned practitioners to enter a trance and bring messages from ancient spirits.
Meanwhile, back in the lab, Araujo is hoping to expand his DMT research to a study of 100 patents.
"Let's say that in five years we'll have... a clear picture on when it will reach a real clinical setting," he said.
Ch.Campbell--AT